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Abstract  29 
 30 
The metabolic fate of a compound is determined by numerous factors including its chemical 31 
structure. Although the metabolic options for a variety of functional groups are well understood, 32 
and can often provide a rationale for comparison of toxicity based on structural analogy, at times, 33 
quite minor structural variations may have major consequences for metabolic outcomes and 34 
toxicity. In this paper, the effects of structural variations on metabolic outcomes is detailed for a 35 
group of related hydroxy- and alkoxy- substituted allyl- and propenylbenzenes. These classes of 36 
compounds are naturally occurring constituents of a variety of botanical based food items. The 37 
classes vary from one another by the presence or absence of alkylation of their para-hydroxyl 38 
substituents and/or the position of the double bond in the alkyl side chain. We provide an 39 
overview of how these subtle structural variations alter the metabolism of these important food-40 
borne compounds, ultimately influencing their toxicity, particularly their DNA reactivity and 41 
carcinogenic potential. The data reveal that detailed knowledge of the consequences of subtle 42 
structural variations for metabolism is essential for adequate comparison of structurally related 43 
chemicals. Taken together, it is concluded that predictions in toxicological risk assessment 44 
should not be performed on the basis of structural analogy only, but should include analogy of 45 
metabolic pathways across compounds and species.  46 
 47 
 48 
 49 
 50 
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Introduction  55 
 56 
The toxicity of chemical compounds is a function of their structure as well as the structure of the 57 
main metabolic products.  The metabolic fate of any compound in a biological system is, in turn, 58 
primarily determined by its chemical structure and specifically the presence of functional groups 59 
and their transformation.  Additional factors that play a critical role in determining the specific 60 
enzymes involved and the kinetics of the metabolic processes include, to various extents, the 61 
dose of the compound, species, stran, sex, co-exposures and genetic factors.  A chemical 62 
structure is defined by not only the overall molecular skeleton, e.g. aromatic or alicyclic 63 
compounds, but also by the type and relative position of functional groups. Minor differences in 64 
chemical structure may result in significant differences in either the biological properties of the 65 
parent compound or in its metabolic fate, and may have major consequences for the biological 66 
activity and therefore toxicity of a compound. In the first case, minor differences in chemical 67 
structure may influence the affinity for a molecular target and thus impact the biological activity 68 
of a compound.  In the second case, apparently minor variations in either the type or the relative 69 
position of functional groups of similar compounds may dramatically alter their properties as 70 
substrates for metabolic enzymes and may result in major differences in the metabolic products.  71 
Consequently, while the metabolic options for a variety of functional groups are well understood, 72 
and can often provide a rationale for comparison of metabolic fate and toxicity based on 73 
structural analogy, the predictions may not always apply.   74 
 75 
The organocyanides (nitriles) provide an illustration of the impact of structural differences on the 76 
toxicity of compounds carrying the same functional group.  The type of molecular skeleton to 77 
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which the nitrile is attached determines the degree of toxicity subsequent to different metabolic 78 
outcomes.  Specifically, nitrile attached to a simple aliphatic skeleton is metabolised to release 79 
toxic hydrogen cyanide, and thus aliphatic nitriles are highly toxic.1-3  However, a nitrile function 80 
directly attached to an aromatic ring is metabolically stable and such organonitriles have low 81 
toxicity.4 A similar example is found in the ability of aliphatic and aromatic carboxylic acids to 82 
undergo conjugation reactions.  Benzoic acid, in which the carbon of the carboxylic acid is 83 
directly attached to the aromatic ring, is conjugated with glycine to form hippuric acid in 84 
humans.5,6 In contrast, phenylacetic acid, the homologue in which the carboxylic acid is attached 85 
on the ring via a spacer of one aliphatic carbon, is conjugated with glutamine to form 86 
phenylacetylglutamine.7 More interestingly, the presence of an alpha-methyl function 87 
(hydratropic acid) on phenylacetic acid results in complete loss of the carboxylic acid’s capacity 88 
to form amino acid conjugates, and it undergoes metabolism by conjugation with glucuronic acid 89 
instead.8 90 
 91 
The influence of subtle structural variations on the biological properties of chemical compounds 92 
is intentionally explored in a variety of chemical applications and in the design of biologically 93 
active, novel molecules with applications in therapeutics, where structure is modified according 94 
to desired pharmacological activity combined with absence of toxicity. Structurally related 95 
substances with different properties can be found as naturally occurring components of plants, 96 
including edible ones, in the form of pharmacologically active principles or flavouring 97 
substances.  For example, 2-hydroxybenzoic acid (salicylic acid) is commonly used for the 98 
treatment of acne and warts, while 3-hydroxybenzoic acid is used as a fragrance ingredient. 99 
 100 
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In this paper the impact of subtle structural variations on metabolism and resulting toxicity is 101 
evaluated for a group of structurally related hydroxy- and alkoxy-substituted allyl- and 102 
propenylbenzenes (Figure 1), which are present naturally as constituents of a variety of edible 103 
plants and are added as flavouring substances in a range of food items. The nine members of the 104 
group examined in this paper are naturally occurring flavouring substances that differ in two 105 
specific structural features: a) the position of the double bond on the alkyl side chain; and b) the 106 
number and alkylation state of the hydroxyl groups on the aromatic ring (Figure 1).  All nine 107 
structures bear an alkyl side chain and a hydroxy or methoxy (alkoxy) moiety on the para-108 
position relative to the alkyl side chain.  In four of the nine structures an additional methoxy- 109 
moiety is present on the meta-position relative to the alkyl side chain.   110 
 111 
A number of food compounds belong to each of these classes: allylalkoxybenzenes include 112 
estragole, methyleugenol and safrole; propenyl alkoxybenzenes include anethole (4-113 
methoxypropenylbenzene) and isoeugenol methyl ether (3,4-dimethoxypropenylbenzene); allyl 114 
hydroxybenzenes include chavicol (4-hydroxyallylbenzene) and eugenol (4-hydroxy-3-115 
methoxyallylbenzene); and propenyl hydroxybenzenes include isochavicol and isoeugenol (4-116 
hydroxy-3-methoxypropenylbenzene).  An overview of the natural occurrence of these 117 
compounds in foods is presented in Table 1.  It is clear from this compilation that plants and 118 
herbs can contain several of these compounds simultaneously and that each compound is found 119 
in several different plants.  Thus, the allylalkoxybenzenes safrole, methyleugenol and estragole 120 
are constituents of nutmeg, cinnamon, anise star, tarragon, sweet basil, and sweet fennel (Table 121 
1), and they are present in the essential oils as well as in food products derived from these plants 122 
(e.g. basil pesto sauce).  The members of hydroxy- and alkoxy-substituted allyl- and 123 
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propenylbenzenes are structural analogues that differ in the number of alkylated hydroxyl 124 
moieties and/or the position of the double bond in the alkyl side chain.  Interestingly, distinct 125 
toxicity has been reported for some but not all of these compounds (Table 2).  Thus, safrole, 126 
methyleugenol and estragole have been reported to have DNA reactivity and show hepatotoxicity 127 
leading to liver tumors in rodents at high dose levels9-15, while the related compounds eugenol, 128 
chavicol, isoeugenol, isochavicol, isoeugenol methyl ether and anethole do not show DNA 129 
reactivity (Table 2).  An overview of the chemical mechanisms responsible for the differential 130 
metabolic fate and subsequent biological properties among these structural analogues is 131 
presented here as a means to understand the ultimate hazard potential of these flavour 132 
substances.  133 
 134 
 135 
A. Toxicity of hydroxy- and alkoxy-substituted allyl- and propenylbenzenes  136 
 137 
The differences in the reported toxicity profiles among the members of these structurally related 138 
groups of hydroxy- and alkoxy-substituted allyl- and propenylbenzenes are intriguing given their 139 
structural similarity and may seem puzzling before their metabolic fate is examined.  A brief 140 
description of their respective toxicity profiles is presented in the following sections.   141 
 142 
A.1. Allylalkoxybenzenes: safrole, methyleugenol and estragole  143 
 144 
There is ample evidence for the carcinogenicity of allylalkoxybenzenes in rodents.  Clear 145 
evidence of hepatocellular adenomas, hepatocellular carcinomas and hepatoblastomas has been 146 
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shown in National Toxicology Program (NTP) studies of methyleugenol, dosing 37, 75, or 150 147 
mg/kg bw/day to B6C3F1 male and female mice by gavage.16 Similar responses were found in 148 
F344/N rats, including increased incidences of hepatocellular adenomas and carcinomas in both 149 
males and females, following administration of 37, 75, 150, and 300 mg/kg bw/day of 150 
methyleugenol by gavage. Furthermore, the incidences of hepatic cholangiomas and hepatic 151 
cholangiocarcinomas were also increased at the two highest dose levels in male rats.16 These 152 
effects have been attributed to the formation of DNA adducts of reactive metabolites, specifically 153 
the 1’-sulfoxy metabolites. Similarly, the hepatocarcinogenicity of safrole and estragole has been 154 
correlated to the formation of their respective 1’-sulfoxy metabolites (Figure 2).9,17-21 The role of 155 
the 1′-sulfoxymetabolite in hepatotoxicity and hepatocarcinogenicity of alkenylbenzenes has 156 
been revealed in experiments by co-administration of the specific sulfotransferase inhibitor 157 
pentachlorophenol (PCP) to mice, which resulted in potent inhibition of hepatic tumour 158 
induction upon long-term dietary administration of safrole or its metabolite, 1'-159 
hydroxysafrole.11,22  160 
The involvement of sulfotransferases in the generation of DNA reactive metabolites was also 161 
demonstrated in genotoxicity studies of 1’-hydroxymethyleugenol using Salmonella typhimurium 162 
TA100 strains expressing human sulfotransferases (SULT), particularly the SULT1A1 and 163 
SULT1C2 isoforms.23  Herrmann et al.24 also studied the role of SULT enzymes in the formation 164 
of hepatic DNA adducts by methyleugenol in vivo. Using FVB/N mice [wild-type (wt)] and 165 
genetically modified strains including a Sult1a1 knockout (ko) strain, a strain transgenic for 166 
human SULT1A1/2 (tg) and for the combination of both modifications (ko-tg), the authors 167 
showed that the adduct formation by both methyleugenol and 1’-hydroxymethyleugenol was 168 
almost completely dependent on the presence of SULT1A enzymes, with human SULT1A1/2 169 
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producing stronger effects than mouse Sult1a1.  Further support for the role of SULTs in the 170 
formation of the DNA adducts of the allylalkoxybenzenes comes from studies reporting reduced 171 
formation of estragole DNA adducts in both in vitro as well as in vivo rat models by the SULT 172 
inhibitor nevadensin, an important flavonoid present in basil.25-27 173 
 174 
A.2. Propenyl alkoxybenzenes: anethole and isoeugenol methyl ether  175 
 176 
The liver is the target organ for anethole toxicity. Anethole induces liver carcinogenicity in 177 
laboratory animals (female Sprague Dawley rats) at high dose levels in the diet.28 Unlike the case 178 
of methyleugenol, it was shown that a non-genotoxic mechanism was responsible for the 179 
neoplastic effects of anethole, involving continuous elevated tissue concentrations and resulting 180 
in hepatotoxicity of its metabolite, anethole epoxide, that in turn leads to regenerative 181 
hyperplasia.29-40 Thus, the liver carcinogenicity of anethole in laboratory animals at high dose 182 
levels is likely due to a non-genotoxic mode of action including cytotoxicity followed by 183 
regeneration of damaged tissue. Data on the toxicity of isoeugenol methyl ether are limited. 184 
 185 
Additional support for a non-genotoxic mechanism for anethole is derived from consistently 186 
negative results for genotoxicity in several in vivo and in vitro studies.  When tested in vitro, 187 
trans-anethole was negative for mutagenicity in Salmonella typhimurium strains TA98, TA100, 188 
TA1535, TA1537, and TA1538, either in the presence or in the absence of metabolic activation 189 
with S-9 at concentrations up to 25,000 µg/plate.29-31,41,42 Similarly, absence of mutagenicity was 190 
reported for anethole in a rec assay in B. subtilis and in a point mutation assay in E. coli43, as 191 
well as in a mutagenicity assay in S. cerevisiae.44 In addition, no increase in chromosomal 192 
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aberrations was observed in Chinese hamster ovary cells treated with anethole, either with or 193 
without S-9 metabolic activation.32 Furthermore, no increase in unscheduled DNA synthesis was 194 
found in studies using primary rat hepatocytes isolated from female SD-CD rats treated with 195 
anethole or anethole-1,2-diol  at concentrations of 10-2 to 10-6 M, or up to the highest dose tested 196 
(0.3 µl/ml). 33-37,45,46 When assessed in a mouse lymphoma forward mutation assay, anethole was 197 
not mutagenic in the absence of metabolic activation. However, in the presence of metabolic 198 
activation, anethole induced forward mutations at the thymidine kinase locus of L5178Y TK+/- 199 
mouse lymphoma cells, although this seems to be the only incidence of mutagenic activity 200 
reported for anethole.30 201 
 202 
Lack of genotoxicity was also reported when anethole was tested in vivo, including in three 203 
independent mouse micronucleus assays. Anethole did not induce either sister chromatid 204 
exchanges (SCE) or chromosomal aberrations in bone marrow cells of B6C3F1 mice injected 205 
intraperitoneally at doses ranging from 2.5 to 2000 mg/kg bw.40,47,48  In a different study, 206 
treatment of Swiss albino mice with 250, 500 or 1000 mg anethole/kg bw/day for 7 days did not 207 
result in an increased number of micronucleated cells in femoral bone marrow cells, even though 208 
target tissue cytotoxicity was documented, as judged by an altered ratio of polychromatic to 209 
normochromatic erythrocytes.49  210 
Consistent with the lack of genotoxicity, there was no significant increase in DNA adducts in 211 
bone marrow cells in B6C3F1 or CD-1 mice treated with 0.7 to 10 mg anethole as a single 212 
intraperitoneal injection.38,39  213 
 214 
 215 
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A.3. Allyl hydroxybenzenes: chavicol and eugenol 216 
 217 
No carcinogenicity has been observed in studies with eugenol in F344/N rats.10,50,51 No 218 
significant dose related increase in the incidences of hepatocellular neoplasms were observed in 219 
either male or female B6C3F1 mice in a 2-year bioassay study.50,51  Eugenol is not genotoxic at 220 
concentrations that do not result in cellular toxicity52-54 and short term toxicity tests did not reveal 221 
hepatotoxicity in rats.53,55,56  This lack of genotoxicity and carcinogencity of eugenol is reflected 222 
in the establishment of an Acceptable Daily Intake (ADI) of 0-2.5 mg/kg bw per day by 223 
JECFA52,53 or of 1.0 mg/kg bw per day  by EFSA.54 Data on the toxicity of chavicol are limited. 224 
 225 
A.4. Propenyl hydroxybenzenes: isochavicol and isoeugenol 226 
 227 
In a 2-year NTP bioassay of isoeugenol in B6C3F1 mice some evidence of increased incidences 228 
of hepatocellular adenoma, hepatocellular carcinoma, and hepatocellular adenoma or carcinoma 229 
(combined) were reported.57 However, these responses were not dose-related and were only 230 
reported in male B6C3F1 mice, a sex and species with historically high levels of background 231 
hepatocellular neoplasms.51 Hepatotoxic or hepatocarcinogenic effects were not observed in 232 
female mice or in either rat sex. Isoeugenol tested negative in various genotoxicity assays57 and 233 
short term toxicity tests in rats did not reveal hepatotoxicity.55 Data on the toxicity of isochavicol 234 
are limited. 235 
  236 
 237 
 238 
 239 
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B. Metabolic pathways  240 
 241 
B.1. Allylalkoxybenzenes: safrole, methyleugenol and estragole  242 
 243 
For this group of structural analogues the 1’-sulfoxy metabolites have been identified as the 244 
ultimate DNA-reactive metabolites responsible for the carcinogenicity.  These metabolites are 245 
the products of sulfotransferase-mediated conjugation of the 1’-hydroxy metabolites, formed 246 
upon 1’-hydroxylation of the allylalkoxybenzenes by cytochromes P450 (Scheme 1).9,17-21 247 
Whether the 1’-sulfoxy metabolite decomposes to give rise to an unstable reactive carbocation 248 
that subsequently reacts with nucleophilic sites in macromolecules including DNA (Scheme 1), 249 
or whether the 1’-sulfoxy metabolite reacts directly with the nucleophilic sites remains to be 250 
elucidated. 251 
 252 
Scheme 1: 253 
 254 
 255 
Formation of the 1’-hydroxy metabolites of allylalkoxybenzenes was demonstrated using human 256 
liver microsomes. Cytochromes P450 1A2, 2C9 and 2C19 were shown to be the primary 257 
enzymes catalyzing the 1’-hydroxylation of methyleugenol58, whereas P450 2C9 and 2A6 were 258 
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identified as the enzymes catalyzing 1’-hydroxylation of safrole59, and P450 1A2 and 2A6 were 259 
shown to be the principle enzymes for 1’-hydroxylation of estragole.60  260 
 261 
Once formed, the 1’-hydroxy metabolites of allylalkoxybenzenes undergo conjugation reactions.  262 
In rats, conjugation with glucuronic acid catalysed by UDP-glucuronosyltransferases (UGTs) 263 
appears to be the major detoxification pathway and results in a stable metabolite which is 264 
excreted in the urine (Scheme 2).61-64  Oxidation of 1’-hydroxy metabolites to the corresponding 265 
ketone has been also identified as an alternative but minor metabolic pathway in rats, whereas it 266 
appeared a major pathway in humans.65-67 In addition, while glucuronidation is the main 267 
conjugation pathway for the 1’-hydroxy metabolites, the keto-metabolite is efficiently 268 
conjugated with GSH.65 Reduction of the keto metabolite back to 1’-hydroxyestragole has also 269 
been observed (Scheme 2).   270 
 271 
Scheme 2: 272 
OH
R
O
O
R
O
GlucO
R
O
major 
human 
pathway
major 
rodent 
pathway
GSH 
conjugationexcretion
 273 
 274 
While the 1’-hydroxylation can lead to downstream bioactivation of safrole, methyleugenol and 275 
estragole, two competing metabolic pathways have been described for this group of compounds.   276 
In the first alternative pathway, O-dealkylation (Scheme 3) competes favourably with 1’-277 
hydroxylation and liberates a free phenolic functional group that provides an efficient 278 
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detoxification option for conjugation and elimination.64,68,69  Epoxidation of the allyl double 279 
bond is the second alternative pathway (Scheme 3). The epoxides of the allylalkoxybenzenes 280 
have been shown to be DNA-reactive and form adducts in vitro.  However, these epoxides were 281 
also shown to be rapidly detoxified by epoxide hydrolases and/or glutathione S-transferases in 282 
vivo.70-74  Therefore, accumulation of these adducts in vivo is considered.71 283 
 284 
Scheme 3: 285 
R
O
R
OH
R
O
O
R
O
OH
OH/SG
epoxide 
hydrolase
glutathione 
S-transferase
epoxidationO-dealkylation
 286 
 287 
Taken together, of three possible metabolic pathways only one leads to the bioactivation of 288 
safrole, methyleugenol and estragole, through the formation of DNA reactive 1’-sulfoxy 289 
metabolites (Scheme 1). This pathway starts with 1’-hydroxylation, followed by sulfate 290 
conjugation, and results in what are currently believed to be the ultimate carcinogenic 291 
metabolites for this class of compounds.11,20,38,39 These electrophiles may react readily with 292 
DNA, RNA and proteins but can also be detoxified through reaction with H2O or conjugation 293 
with glutathione.39,76-78 Therefore, only a fraction of the 1’-sulfoxy metabolite is expected to 294 
form DNA adducts.  295 
 296 
The types of DNA adducts formed have been examined for estragole in vitro (Figure 2). The 297 
major adduct formed was with the guanine base, specifically the N2-(trans-isoestragol-3'-yl)-298 
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deoxyguanosine (E-3'-N2-dG).  Other adducts included N2-(estragol-1'-yl) deoxyguanosine (E-1'-299 
N2-dG), 7-(trans-isoestragol-3'-yl)-deoxyguanosine (E-3’-7-dG), and 8-(trans-isoestragol-3'-yl)-300 
deoxyguanosine (E-3’-8-dG).75,79 Adducts of estragole with deoxyadeninosine, such as N6-301 
(trans-isoestragol-3'-yl)-deoxyadenosine (E-3'-N6-dA), are also formed to a significant extent in 302 
the liver of male rats (F344) exposed to 600 mg/kg bw of estragole for 4 weeks.78 The structure 303 
of these adducts is consistent with initial formation of the 1’-sulfoxy metabolite of estragole, and 304 
the loss of the sulfate moiety which is facilitated by resonance stabilisation via isomerisation of 305 
the allylic double bond from the C2’-C3 to the C1’-C2’ position, and the presence of the para-306 
methoxy substituent on the phenyl ring.80 307 
 308 
Herrmann et al.81 reported the detection of similar adducts of methyleugenol in surgical human 309 
liver samples from 30 subjects. Using isotope-dilution ultra-performance liquid chromatography-310 
tandem mass spectrometry (UPLC-MS/MS), they detected N2-(trans-methylisoeugenol-3'-yl)-2'-311 
deoxyguanosine adducts (Figure 3) in 29 liver samples as the major adduct and N6-(trans-312 
methylisoeugenol-3'-yl)-2'-deoxyadenosine (Figure 3) at lower levels in most samples as well. 313 
The maximal and median levels of both adducts combined were 37 and 13 adducts per 108 314 
nucleosides. 315 
 316 
The biotransformation of these substances and the likely formation of DNA adducts is both dose-317 
dependent and species-specific. Conversion by O-dealkylation to metabolites with a free 318 
phenolic functional group that can be readily excreted with or without conjugation is the 319 
predominant route of biotransformation for this group of compounds at low doses in rodents and 320 
humans.64,68,69,82,83 In contrast, oxidation of the allyl side chain that generates 1’-hydroxy 321 
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metabolites and alkene epoxides occurs at higher dose levels.64,68  Rodent toxicity and 322 
carcinogenicity studies typically employ high dose levels, thus favouring the latter metabolic 323 
pathways. This is demonstrated by the results of studies reporting that the metabolite profile of 324 
safrole changed in a dose-dependent fashion over a range of oral dose levels of 0.9, 60 or 600 325 
mg/kg bw.  As predicted, a shift from mainly O-dealkylated metabolites detected at lower dose 326 
levels to 1’-hydroxylation products on the allyl side chain and/or epoxide formation was 327 
observed that was more prominent when the dose increased from 60 to 600 mg/kg bw.62 A 328 
similar shift in metabolic profile of estragole was reported in another study in mice and rats. As 329 
the dose increased (0.05, 5, 50, 500,1 000 mg/kg bw), the relative extent of O-demethylation 330 
decreased with a parallel increase in 1’-hydroxylation, the latter amounting to 1.3, 2.1, 5.2, 7.8 331 
and 9.4% of the dose at increasing dose levels in the mouse study.64,68 This dose-dependent 332 
metabolic shift from O-demethylation to 1'-hydroxylation was consistent with the results of 333 
pharmacokinetic modeling using a physiologically based kinetic (PBK) model developed for 334 
estragole bioactivation and detoxification in the male rat (Punt et al., 2008). The main metabolic 335 
pathway of estragole at low doses was shown to be O-demethylation. Saturation of the O-336 
demethylation pathway was shown to occur at higher doses of estragole leading to increased 337 
relative formation of  1'-hydroxyestragole.  338 
In contrast to this, a study on hepatic DNA adduct formation in mice exposed to methyleugenol 339 
did not provide an indication of a dose dependent metabolic shift.24 Also, Gupta et al.85 reported 340 
a nearly linear dose response curve for hepatic DNA adduct formation upon exposure of mice to 341 
a dose range of safrole varying from 0.001 to 10 mg per mouse. This linear dose response 342 
behaviour is also in line with results from physiologically based kinetic (PBK) modelling, which 343 
predicted that formation of the reactive sulfoxy metabolites and the resulting DNA adducts 344 
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formed upon exposure to methyleugenol, estragole or safrole would be linear with the dose at 345 
dose levels as high as the ones causing tumors in rodent bioassays down to dose levels in the 346 
range of realistic human exposure.66,67,86,88 It might be that the metabolic shift occurs especially 347 
at dose levels higher than the ones causing tumors in rodent bioassays. 348 
 349 
Overall, these studies demonstrate that a reactive intermediate carbocation is the ultimate 350 
carcinogenic metabolite by virtue of DNA adduct formation. The generation of the carbocation 351 
in this group of related para-allylalkoxyalkylbenzenes is the result of a bioactivation pathway 352 
involving cytochrome P450-mediated allyl side chain 1’-hydroxylation followed by sulfate 353 
conjugation of the hydroxyl moiety to form the 1’-sulfoxy metabolite. The presence of a 2,3-354 
unsaturated allyl side chain provides the activated carbon (C1), which is both allylic and benzylic 355 
and serves as the required electrophilic moiety. The overview also suggests that O-dealkylation 356 
that liberates a hydroxyl moiety is an efficient detoxification pathway that facilitates excretion.  357 
Several species differences have been identified in the relative contribution and efficiency of 358 
metabolic pathways involved in the biotransformation of allylalkoxybenzenes.  Among the three 359 
main pathways, namely O-dealkylation, allyl chain epoxidation and allyl chain 1’-hydroxylation, 360 
evidence has shown that O-dealkylation appears to be more favoured in the mouse and human 361 
than in the rat at comparable doses.64,68,69  Consistent with this difference, the metabolic shift 362 
from O-dealkylation to 1’-hydroxylation of the allyl side chain with increasing dose is more 363 
significant and readily observed in rats compared to mice.10,20,75 In addition, in rats, a clear dose-364 
dependent increase in 1’-hydroxysafrole or its downstream metabolites is observed in the urine, 365 
whereas no evidence was found of such metabolites occurring in humans at low dose (1.66 mg; 366 
~0.03 mg/kg bw).62  In in vitro incubations the metabolic fate of the 1’-hydroxyl moiety toward 367 
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oxidation or conjugation appeared to be species dependent. Oxidation to the ketone, which is 368 
efficiently scavenged by GSH, appeared to be a minor pathway for 1’-hydroxyestragole 369 
conversion inincubations with rat liver microsomes,  compared to 1’-hydroxyl glucuronidation84, 370 
but appears to be the major pathway for conversion of 1’-hydroxyestragole in incubations with 371 
human liver microsomes.65  In spite of this species difference, the formation of 1’-372 
sulfoxyestragole was found to vary less than 2-fold between rat and human.65 Studies with 1’-373 
hydroxymethyleugenol and 1’-hydroxysafrole have also revealed the same species-specific 374 
differences between glucuronidation and oxidation routes of metabolism as well as a similar 375 
relatively small difference in the formation of the 1’-sulfoxy metabolite between rat and 376 
human.66,67   377 
 378 
B.2. Propenyl alkoxybenzenes: anethole and isoeugenol methyl ether  379 
 380 
Anethole and isoeugenol are the propenyl relatives of estragole and methyleugenol, respectively, 381 
as a result of isomerisation of the double bond in the allyl side chain (Figure 1). Anethole 382 
epoxide has been determined to be the ultimate hepatotoxic metabolite of anethole based on 383 
extensive biochemical and toxicological data.88 The target organ for anethole toxicity is the liver 384 
where anethole epoxide has been shown to be 10 times more potent and exhibit hepatocellular 385 
cytotoxicity at concentrations 10 times lower compared to those of anethole itself.33-37,89 The 386 
primary role of the epoxide is also corroborated by the increase in the hepatotoxic effects of 387 
anethole that are observed in freshly isolated rat hepatocytes in the presence of inhibitors of 388 
enzymes responsible for anethole epoxide detoxification, such as epoxide hydrolase and 389 
glutathione S-transferase.35 Furthermore, from data based on species and sex differences it can 390 
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be seen that the higher the rate of daily production of anethole epoxide, i.e. the more efficient the 391 
formation of the active metabolite, the lower the dose levels of anethole that result in signs of 392 
hepatotoxicity.88,90 A correlation between the rate of conversion of anethole to anethole epoxide 393 
and the hepatotoxic effects observed in short-term and long-term rodent studies have been 394 
quantitatively demonstrated.28  395 
 396 
Efficient detoxification of anethole epoxide in vivo, by epoxide hydrolase and/or glutathione S-397 
transferases, is likely at low doses and maintains the epoxide metabolite at non-hepatotoxic 398 
levels. Similar observations have been reported in the case of the epoxides of the 399 
allylalkoxybenzenes70-74, such that the epoxide DNA adducts shown to form in vitro, are 400 
considered unlikely to accumulate in vivo at low doses.71 401 
 402 
An alternative metabolic pathway for propenyl alkoxybenzenes is the 3’-hydroxylation of the 403 
side chain (Scheme 4) and this is the main route in humans at low dose levels.91 Following 3’-404 
hydroxylation, trans-anethole is efficiently detoxified via subsequent β-oxidation that yields 405 
para-methoxy benzoic acid (Scheme 4), followed in turn by rapid conjugation with glycine and 406 
elimination in the urine.82,91 This pathway competes effectively with epoxidation at low dose 407 
levels, making bioactivation and toxicity less likely. Therefore, at low dose levels, epoxidation is 408 
a minor pathway and is quantitatively similar among mice, rats, and humans albeit slightly more 409 
prominent in the rat compared to the mouse or human.  410 
 411 
 412 
 413 
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Scheme 4: 414 
 415 
 416 
The shift between 1’-hydroxylation and 3’-hydroxylation of the side chain is an illustration of the 417 
metabolic and toxicological impact that results from a small structural difference between 418 
isomers, comparing those with an allyl double bond and those with a propenyl double bond in 419 
the side chain. The change in the location of the double bond results in a different 420 
regioselectivity of the cytochrome P450 catalysed reaction resulting in the formation of  a non-421 
genotoxic metabolic intermediate (3’-hydroxy-) instead of the proximate carcinogenic metabolite 422 
(1’-hydroxy-).  By extension, the location of the double bond shifts the toxicological profile from 423 
that of DNA adduct-forming genotoxic compounds to that of non-genotoxic ones which are 424 
readily conjugated and rapidly excreted in the urine.  425 
 426 
Additional metabolic options for detoxification are available in compounds with an additional 427 
methoxy substituent at the meta-position, as in the case of isoeugenol methyl ether. The 428 
additional methoxy group increases the probability of detoxification via O-demethylation and 429 
subsequent conjugation of the hydroxyl group with a concomitant reduction in the formation of 430 
the corresponding epoxide.92 The fraction of metabolites resulting from the epoxidation pathway 431 
account for less than 1% of the urinary metabolites detected in male Wistar rats administered a 432 
single oral dose of 200 or 400 mg isoeugenol methyl ether/kg bw. The majority of urinary 433 
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metabolites, greater than 77%, were products of 3- and 4-O-demethylation and 3’-hydroxylation. 434 
The extent of hepatotoxic effects reported for isoeugenyl methyl ether is directly correlated to the 435 
levels of formation of the corresponding epoxide. Taken together, exposure to anethole and 436 
isoeugenol methyl ether at dose levels relevant for human dietary intake is consistent with 437 
absence of toxicity given the efficient detoxification that occurs at similar levels in rodents and 438 
humans. It is only in the context of chronic exposure to high dose levels in female rats that the 439 
continuous daily production of hepatotoxic concentrations of anethole epoxide has been shown 440 
to occur which in turn results in a continuum of cytotoxicity, cell death, regenerative cell 441 
proliferation, and following prolonged exposure, liver tumors. The relationship between high-442 
dose anethole exposure, epoxide formation and hepatotoxicity has been also assessed 443 
quantitatively in a 2-year study using female rats.28 A higher fraction of anethole was converted 444 
to the epoxide with higher dose of parent compound.  A dose of 200 mg/kg bw per day of 445 
anethole resulted in 15% epoxide metabolites, with an estimated epoxide dose of 30 mg/kg bw 446 
per day, whereas a dose of 550 mg/kg bw per day of anethole resulted in 23% epoxide 447 
metabolites, with an estimated epoxide dose of 120 mg/kg bw per day and a proportional 448 
increase in the incidence and severity of hepatotoxicity.88  A clear threshold of anethole 449 
hepatoxicity can be determined, as shown by the absence of hepatotoxicity at a dietary dose of 450 
120 mg/kg bw per day of anethole and an estimated epoxide dose of approximately 22 mg /kg 451 
bw per day. Female rats exhibited both hepatic toxicity and hepatic tumors at the highest dietary 452 
dose of anethole (550 mg/kg bw per day).  By comparison, human exposure to anethole is 453 
estimated to be a daily intake of 0.002 mg/kg bw, orders of magnitude below the no-effect dose 454 
in rodents. Clearly, a large margin of safety exists between dose levels causing hepatotoxicity in 455 
experimental animals and levels expected to occur in realistic human exposure scenarios.  456 
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 457 
Thus, comparison of the metabolic profile of anethole and isoeugenyl methyl ether to that of the 458 
related allylalkoxybenzenes safrole, methyleugenol and estragole, reveals that a small structural 459 
difference such as the isomerisation of the double bond in the allyl side chain results in distinct 460 
metabolic pathways that favor detoxification.  461 
 462 
Metabolic studies have shown that at low dose levels (<5 mg/kg bw/day) anethole is rapidly 463 
absorbed and detoxified in rodents primarily by O-demethylation and in humans primarily by 3’-464 
hydroxylation (scheme 4).82,89,91,93 465 
 466 
B.3. Allyl hydroxybenzenes: chavicol and eugenol  467 
 468 
Chavicol and eugenol are allyl hydroxybenzenes and the structural analogues of methyleugenol 469 
and estragole, respectively, lacking the methoxy substituent but containing a hydroxyl moiety 470 
para- to the allyl side chain (Figure 1). Thus, the presence of a free hydroxyl moiety on the ring 471 
accounts for the difference in toxicity of eugenol and chavicol compared to that of 472 
methyleugenol and estragole. The free phenolic function allows conjugation to become a primary 473 
mode of metabolism and excretion (Scheme 5). Additional metabolic options for eugenol 474 
include: a) isomerization to yield isoeugenol, with the subsequent paths to epoxidation of the 475 
allyl double bond yielding an epoxide that hydrolyzes to the corresponding diol; b) 476 
hydroxylation at the allyl position to yield 1’-hydroxyeugenol; c) O-dealkylation at position 3’ of 477 
the ring to yield 3,4-dihydroxypropenylbenzene; or d) reduction of the double bond of the side 478 
chain to yield 3-methoxy-4-hydroxypropylbenzene (Scheme 5). Compared to the primary 479 
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metabolic pathway of para-hydroxyl conjugation, these alternatives all yield minor metabolites 480 
that are not of toxicological concern.  481 
 482 
Scheme 5 483 
 484 
 485 
Conjugation with glucuronic acid or sulfate is efficient for all of these metabolites, which 486 
possess a free phenolic hydroxyl group or other polar oxygenated functional groups and results 487 
in rapid renal elimination.94 The metabolic fate of eugenol has been demonstrated in fasted 488 
humans (n=2), where 94 and 103% of a dose of approximately 6.4 µg/kg bw [14C]-eugenol was 489 
excreted in conjugated form in the 24-hour urine. Of these urinary conjugates, over 85% was 490 
accounted for by predominantly glucuronic acid conjugates of eugenol, followed by sulfate 491 
conjugates.95 In a separate trial in human volunteers (n=8), who received a single dose of 150 mg 492 
of eugenol (approximately 2.5 mg/kg bw) in gelatin tablets after consumption of a normal 493 
breakfast, more than 55% of the eugenol dose was excreted in the urine as the glucuronic acid or 494 
sulfate conjugates within 24 hours. An additional 40% of the dose was accounted for by other 495 
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conjugated metabolites of isomerized, epoxidized, or reduced forms of eugenol. In total, 496 
conjugated eugenol and its conjugated metabolites accounted for >95% of the administered dose, 497 
while unconjugated eugenol accounted for less than 0.1%.94 The authors concluded that eugenol 498 
undergoes rapid first pass conjugation and rapid elimination.94  499 
 500 
Even though eugenol and chavicol share the allyl side chain with methyleugenol and the 501 
allylalkoxybenzenes, the free phenolic hydroxyl moiety is a major structural difference that 502 
increases possibilities for swift conjugation and excretion, which likely explains the absence of 503 
DNA reactivity and carcinogenicity for eugenol compared to methyleugenol.16,51 The metabolic 504 
fate of eugenol in rodents is reported to be similar to that in humans with respect to rapid 505 
conjugation and elimination.95,96 However, sulfate conjugates appear to be the primary 506 
metabolites, while glucuronic acid conjugates seem to form as a result of saturation of sulfate 507 
conjugation pathways. Thus, at least in rodents, the type of conjugates also seems to be dose-508 
dependent, with sulfate conjugates being the principle metabolites at low doses (0.5, 5, and 50 509 
mg/kg bw), and glucuronic acid conjugates predominating at the highest dose (1000 mg/kg bw).  510 
 511 
B.4. Propenyl hydroxybenzenes: isochavicol and isoeugenol  512 
 513 
This group, represented by isochavicol and isoeugenol, combines two structural differences 514 
relative to the allylalkoxybenzenes, namely isomerisation of the allyl side chain and replacement 515 
of the para-methoxy substituent by a para-hydroxyl moiety. Both changes convert 516 
methyleugenol to isoeugenol, while the isomerisation of the allyl side chain distinguishes 517 
isoeugenol from eugenol (Figure 1). The equivalent changes distinguish isochavicol from 518 
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estragole and chavicol, respectively. Anethole and isochavicol share the propenyl side chain and 519 
differ only in the presence of the free phenolic group. A dramatically different toxicity profile is 520 
also observed for the propenyl hydroxybenzenes compared to the allylalkoxybenzene relatives as 521 
a result of different metabolic fates associated with the presence of a hydroxyl substituent at the 522 
para-position in combination with the shift in the double bond in the allyl side chain.  As 523 
expected, the predominant detoxification pathway for isoeugenol is the conjugation of the free 524 
phenolic function with sulfate and glucuronic acid. Indeed, greater than 85% of [14C]-isoeugenol 525 
administered at a dose of 156 mg/kg bw by gavage to male Fischer-344 rats is excreted in the 526 
urine within 72 hours as the glucuronic acid and sulfate conjugates.97 Intravenous administration 527 
results in a similar metabolic and elimination pattern with 82% of a 15.6 mg/kg bw dose of [14C]-528 
isoeugenol excreted as the same urinary conjugates within 72 hours. Regardless of 529 
administration route, the remaining dose was accounted for with approximately 10% excreted in 530 
the feces, up to 0.1% recovered as expired CO2, and less than 0.25% remaining in selected 531 
tissues.  The conclusion that isoeugenol does not present a carcinogenic hazard is consistent with 532 
the efficient detoxification of isoeugenol, due to its free phenolic hydroxyl, similar to the group 533 
of allyl hydroxybenzenes.  534 
 535 
Conclusions  536 
 537 
A mechanism-based approach has been taken to illustrate how minor structural changes may 538 
result in different metabolic pathways of either bioactivation or detoxification with a significant 539 
impact on the toxicological outcome. The impact of small structural differences on toxicity is 540 
important to consider when using structural analogy as a rationale for predictions in toxicity 541 
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assessment. The structural similarities and differences among allylalkoxybenzenes, propenyl 542 
alkoxybenzenes and their allyl and propenyl hydroxybenzene relatives were presented in this 543 
paper as examples.  When viewed in the context of their metabolic fate, it is clear that structural 544 
features alone are not adequate as the basis for comparative toxicity assessment. Comparative 545 
approaches are more effective in assessing toxicity when based on a combination of both 546 
structural analogy and metabolic analogy as has been demonstrated here by comparing the 547 
metabolic fate and toxicity outcomes of structurally related substances naturally occurring in 548 
foods that differ only in the position of the double bond of the alkenyl side chain and/or in the 549 
presence of a para-hydroxy or para-methoxy functional group. The relationship between 550 
chemical structure and ADME (absorption, distribution, metabolism and excretion) 551 
characteristics determines whether detoxification or bioactivation of the parent compound may 552 
occur and whether effective elimination of metabolites may follow. The impact of subtle 553 
structural changes on the metabolic fate for the four types of substances demonstrates that a 554 
mode-of-action-based approach that includes both parent compound and metabolites can more 555 
accurately evaluate the potential toxicity, DNA reactivity and carcinogenicity of these related 556 
food constituents. It is concluded that isomerisation of the double bond in the allyl side chain 557 
and/or the presence of a free phenolic hydroxyl moiety shifts the metabolism in favour of 558 
detoxification and eliminates the possibilities for formation of a DNA reactive carcinogenic 559 
metabolite. It is with this insight that the remarkable differences in the toxicity of these related 560 
hydroxy- and alkoxy-substituted allyl-and propenyl-benzenes can be explained. It also illustrates 561 
how subtle structural changes among parent compounds that do not seem critical in and of 562 
themselves can have significant effects on toxicity simply due to critical divergence in the 563 
relevant metabolic products. Furthermore, species differences in relative metabolic pathway 564 
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contributions to biotransformation of a compound must also be taken into account, as illustrated 565 
in the case of the allylalkoxybenzenes by the preferential formation of the 1’-hydroxy metabolite 566 
and its glucuronidated product in rodents but an oxo-metabolite and its glutathione conjugate in 567 
humans. It is concluded that comparisons in toxicological risk assessment should be done on the 568 
basis of structural analogy, not only of the parent compounds but also for the metabolic products 569 
with due consideration to species-specific metabolic pathways.  570 
  571 
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Table 1. Occurrence of allylalkoxybenzenes in the modern food chain.98  905 
 906 
Substance Natural occurrence in Food 
Anethole Anise hyssop, fresh apple, fennel, buckwheat, caraway, cheese, cherimoya, 
clove, coriander seed, dill seed, elder glower, ginger, green tea, juniper 
berry, lemon balm, licorice, mastic, mustard, myrtle berry, basil, ouzo, 
passion fruit,  pastis, pepper, peppermint oil, piper betle, rhubarb, star anise, 
sweet grass oil, sweet marjoram 
Chavicol Apple brandy, cassia leaf, chervil, cider, cloudberry, clove bud, clove stem, 
galangal, basil, passion fruit juice, pimento berry and leaf, pineapple, piper 
betle, rosemary, sour cherry, sweet marjoram, wheaten bread 
Estragole Anise, anise hyssop, fresh apple, apple juice, bilberry, fennel, nutmeg, 
chervil, cider, cinnamonium, cinnamon bark, clove bud and leaf, coriander 
seed, elder flower, Korean mint, laurel, lemon balm, licorice, mastic, 
mustard, myrtle berry and leaf, basil, orange juice, passion fruit, pimento 
berry and leaf, piper betle, rosemary, sage, star anise, sweet fennel, sweet 
grass oil, sweet marjoram, tarragon, grapes 
Eugenol Honey, acerola, American cranberry, anise, anise hyssop, apple brandy, 
fresh apple, apricot, arctic bramble, Armagnac, Ashanti pepper, banana, 
beer,  stone apple, bilberry, black choke berry, black currents, blackberry, 
porcino mushrooms, botrytised wine,  bourbon vanilla, bourbon whiskey, 
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buchu oil, buckwheat, calamus, Canadian whiskey, bell pepper, carrot, 
cassia leaf, celery seed oil, chervil, Chinese quince, cider, cinnamon bark,  
leaf and root bark, clary sage, cloudberry, clove bud, leaf and stem, cocoa, 
coffee, cognac, crispbread, cuttlefish, dill herb and seed, elder flower, 
elderberry juice, European cranberry, smoked fatty fish, fenugreek, fig, 
ginger, globe artichoke, grape brandy, grapefruit oil, green mate, guava 
fruit, blueberry, Indian dill seed, Irish whiskey, Japanese whiskey, dried 
bonito, Korean mint, kumquat oil, lamb’s lettuce, laurel, smoked lean fish, 
lemon peel oil, licorice, lime oil, lingonberry, macadamia nut, mace, malt 
whiskey, mango, mastic, mate, melon, myrtle leaf, basil, okra, orange juice, 
orange oil, oregano, ouzo, passion fruit, pennyroyal oil, pepper, peppermint 
oil, pimento berry and leaf, piper betle, plum, plum brandy, plum wine, 
pickled plum, quince, raspberry, red wine, rhubarb, rose wine, rosemary, 
rum, sage, Scotch blended whiskey, Scotch spearmint oil, sea buckthorn, 
sherry, sour cherry, sage, spearmint oil, strawberry, savory, sweet cherry, 
sweet grass oil, sweet marjoram, tamarind, Caja fruit, tarragon, tequila, 
thyme, fresh tomato, tomato juice and paste, wax jambu, white wine, yuzu 
oil   
Ischavicol Apple cider 
Isoeugenol Apple brandy, beer, bilberry, blackberry, Chinese quince, cinnamon leaf, 
clove bud and stem, coffee, cuttlefish, dill seed, elder flower, smoked fatty 
fish, grapefruit juice, green tea, guava fruit, blueberry, dried bonito, mace, 
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malt, mate, mushroom, nutmeg, pimento leaf, piper betle, plum, rum, 
thyme, fresh tomato, wort , yuzu oil 
Methyl 
eugenol 
Anise hyssop, apple brandy, fresh apple, arctic bramble, Ashanti pepper, 
banana, bilberry, black tea, blackberry, buchu oil, buckwheat, calamus, 
cardamom, carrot, chervil, Chinese quince, cinnamomum, clove bud and 
leaf, cognac, lemon grass oil, eucalyptus oil, grapefruit juice, galangal, hog 
plum, kaboso oil, dried bonito, Korean mint, kumquat oil, laurel, lemon 
balm, lovage seed, mace, mastic, myrtle berry and leaf, nutmeg, basil, 
orange juice and oil, parsnip, peach, pepper, pimento berry and leaf, piper 
betle, plum, prune, quince, rosemary, sapodilla fruit, sherry, star anise, 
strawberry guava, sweet grass oil, tarragon, grapes  
Isoeugenol 
methyl 
ether  
Calamus, ginger, dried bonito, mastic, orange oil, citrus fruits, nutmeg, 
tarragon, calamus, dill, soursop 
 
Safrole Acerola, Ashanti pepper, banana, cinnamomum, cinnamon bark, leaf and 
root bark, cocoa, coriander seed, dill herb, green mate, dried bonito, 
kumquat oil, lemon balm, macadamia nut, mace, nutmeg, basil, pepper, 
piper betle, star anise, tamarind 
 907 
  908 
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Table 2. Summary of hepatotoxicity, genotoxicity and carcinogenicity of the hydroxy- and 909 
alkoxy-substituted allyl- and propenylbenzenes. 910 
compounds hepatotoxicity genotoxicity carcinogenicity 
Allylalkoxybenzenes  
             (estragole, methyleugenol, safrole) 
  + + + 
Propenyl alkoxybenzenes  
             (anethole, isoeugenol methylether) 
  + - + 
Allyl hydroxybenzenes  
             (chavicol, eugenol) 
  - - - 
Propenyl hydroxybenzenes  
            (isochavicol, isoeugenol) 
  - - - 
 911 
  912 
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Figure legends  913 
 914 
Figure 1. Structural formulas of the hydroxy- and alkoxy- substituted alkyl- and 915 
propenylbenzenes included in the present structure activity analysis.  916 
 917 
Figure 2. Schematic presentations of DNA adducts formed with allylalkoxybenzenes using 918 
estragole as the model compound: N2-(trans-isoestragol-3'-yl)-deoxyguanosine (E-3’-N2- 919 
dG), N2-(estragol-1'-yl)-deoxyguanosine (E-1’-N2-dG), 7-(trans-isoestragol-3'-yl)- 920 
deoxyguanosine (E-3’-7-dG), 8-(trans-isoestragol-3'-yl)-deoxyguanosine (E-3’-8-dG), and N6-921 
(trans-isoestragole-3'-yl)-deoxyadenosine (E-3'-N6-dA).75,79  922 
 923 
Figure 3. Schematic presentations of methyleugenol DNA adducts detected in surgical human 924 
liver samples: N2-(trans-methylisoeugenol-3'-yl)-2'-deoxyguanosine (ME-3’-N2-dG) and N6-925 
(trans-methylisoeugenol-3'-yl)-2'-deoxyadenosine (ME-3'-N6-dA).81  926 
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 927 
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 933 
Figure 2. 934 
 935 
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 937 
 938 
Figure 3. 939 
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